Source: Annual Congress 2002 - Cell biology and genetics of COPD and emphysema
Disease area: Airway diseases

Abstract

Vasoactive Intestinal Peptide (VIP) is a neuropeptide acting on its target cells through two receptors, VIPR1 and VIPR2. We have previously shown that VIPR1 expression was increased in the bronchial glands and vessels of smokers with symptoms of chronic bronchitis as compared to asymptomatic smokers (Mapp et al., ATS International Conference 2002). The aim of this study was to quantify the VIPR2 expression in central airways of smokers with symptoms of chronic bronchitis (CB) as compared to asymptomatic smokers (AS). Lung tissue was obtained from surgical specimens of 7 AS with normal lung function and 14 CB [6 with normal lung function and 8 with chronic airflow obstruction (COPD)]. Immunohistochemistry was performed using a monoclonal antibody specific for human VIPR2. VIPR2 expression was observed in bronchial epithelium, smooth muscle, glands and vessels. The receptor expression was quantified in bronchial glands and vessels by using light microscopic analysis. The percentage of VIPR2 +acini/total acini and of +vessels/total vessels was similar in smokers with CB as compared to AS. In these airway compartments, dividing smokers with CB according to the presence of chronic airflow obstruction, no differences were found in patients with CB and normal lung function and in patients with COPD as compared to AS. In conclusion, we have shown that VIPR2 expression is not modified in the central airways of patients with chronic bronchitis with normal lung function or with chronic airflow obstruction.
Supported by: MURST, A.R.C.A., Consorzio Ferrara Ricerche and Boehringer Ingheleim.

Rating:

Share or cite this content

Citations should be made in the following way:
A. Rambaldi, C. Piola, I. Bononi, D. Miotto, P. Boschetto, G. Casoni, A. Papi, L. M. Fabbri, C. E. Mapp (Ferrara, Modena, Italy). Vasoactive intestinal peptide receptor 2 (VIPR2) in central airways of smokers. Eur Respir J 2002; 20: Suppl. 38, 635

Member's Comments

No comment yet.

Related content which might interest you: Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis Source: Eur Respir J 2004; 24: 958-963 Year: 2004 Concentration of vasoactive intestinal peptide (VIP) and substance P (SP) in bronchi of patients with mild to moderate bronchial asthma Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005 Vasoactive intestinal peptide (VIP) supresses ACE2- and TMPRSS2 expression in stimulated epithelial cells Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease Year: 2021 Distribution of vasoactive intestinal peptide( VIP)- and substance P (SP)- containing innervation in bronchi of patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Serum level of VIP (vasoactive intestinal polypeptide) in patients with COPD in stable state and during exacerbation Source: Eur Respir J 2001; 18: Suppl. 33, 483s Year: 2001 Vitamin C, VIP (vasoactive intestinal polypeptide) and gastrin in the serum of COPD patients in stable state and during exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 259s Year: 2002 VIP (vasoactive intestinal polypeptide) and vitamin C in the serum of COPD patients before and after therapy Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 Vasoactive intestinal peptide (VIP) for treatment of COPD: improvement in spiroergometry and 6 minute walking distance Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 The vasoactive effects of helospectins I and II in vivo are not mediated by VIP and PACAP1-38 receptors or vasodilator prostaglandins Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Expression vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Protection of vasoconstriction and lung function impairment by endothelin-receptor blockers and vasoactive intestinal peptide (VIP) in isolated perfused rat lungs Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea Source: Eur Respir J 2003; 21: 3-10 Year: 2003 Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Immunohistochemical relationship between transient receptor potential vanilloid-1 (TRPV1) and neuropeptide (CGRP, Substance P) in the guinea pig respiratory system Source: Eur Respir J 2005; 26: Suppl. 49, 364s Year: 2005 Inhaled vasoactive intestinal peptide exerts immune-regulatory effects in patients with sarcoidosis Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Vasoactive intestinal peptide-receptor regulation in monocytes derived from COPD patients Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Vasoactive and growth factors in pulmonary emphysema Source: Annual Congress 2010 - Pulmonary vascular involvement in COPD Year: 2010 N-formyl Met-Leu-Phe (fMLP), a microbe-derived chemoattractant for leukocytes, activates porcine airway submucosal gland acinar cells Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 Neuropeptide regulation of secretion and inflammation in human airway gland serous cells Source: Eur Respir J, 55 (4) 1901386; 10.1183/13993003.01386-2019 Year: 2020